Arterialrestenozis: past, present, future

• Kirill A. Khokhlov
• Kirill L. Kozlov
• Evgeniy O. Lebedenko
• Viktoriya O. Polyakova
• Gleb B. Saraev
• Olga V. Simonova

Abstract

Relevance. Currently, arterial restenosis is the main problem of X-ray endovascular surgery. Thus, the vessel’s lumen narrowing re-development reduces the use of open and percutaneous arteries reconstruction methods. Actually, restenosis itself is a narrowing of the vessel’s lumen by more than 50% after damage to the vessel wall in the process of its restoration, usually developing 6–9 months after angioplasty. According to the literature, the incidence of restenosis in the coronary arteries ranges from 10 to 40% depending on the angiographic and clinical situations. The occurrence of restenosis in the arteries of the lower extremities ranges from 34 to 46% when using the balloon angioplasty method and from 1.6 to 19.4% when vascular stenting.

The aim and objectives of the study. To review and analyze current literature data on the problem of arterial restenosis in patients after arterial reconstruction and the modern approach to preventing the problem.

Material and methods. Electronic databases were searched, including PubMed, Googleacademy, Cyberleninka and Web of science, a deep search of 10 years on key aspects.

Keywords:acute restenosis; drug-eluting stent; neointima

References

1. Kozlov K.L., Paltseva E.M., Polyakova V.O., Tishko V.V. Arterial restenosis. Molecular biomedical aspects. St. Petersburg: Eco-Vector, 2017, pp. 42–51. (in Russian)

2. Arsenicheva O.V. Role of endothelial dysfunction and metabolic syndrome in interventional treatment complications development in patients with coronary heart disease. Kazanskiy meditsinskiy zurnal [Kazan medical journal]. 2013; 94 (2): 152–7. DOI: https://doi.org/10.17816/KMJ1579

3. Ioseliani D.G., Asadov D.A., Fomenko V.V., Azarov A.V., Semitko S.P. Five-year outcomes of implantation of Absorb biodegradable stents using the bifurcation stenting technique: a case report. Кардиоваскулярная терапия и профилактика Kardiovaskulyarnya terapiya i profilaktika [Cardiovascular therapy and prevention]. 2021; 20 (4): 2864. DOI: https://doi.org/10.15829/1728-8800-2021-2864 (in Russian)

4. Polyakov R.S., Abugov S.A., Mardanyan G.V., Saakyan Yu.M., Puretsky M.V., Pirkova A.A., Boltenkov A.V., Naumov S.M. Twelve months clinical outcomes of PCI using sirolimus and everolimus-eluting stents. Aterotromboz [Atherotrombosis]. 2013; (1): 9–20. DOI: https://doi.org/10.21518/2307-1109-2013-1-9-20 (in Russian)

5. Karpasova E.A., Diatlova A.S., Linkova N.S., Bunin V.A., Polyakova V.O., Krylova Yu.S., Kvetnoy I.M. Troponins, adhesion molecules and interleukins as diagnostic markers of cardiovascular diseases: expression in peripheral tissues. Uspekhi sovremennoy biologii [Frontiers of modern biology]. 2020; 140 (1): 30–42. (in Russian)

6. Belonosov D.A., Lebedeva A. Yu., Gordeev I.G. Features of inflammation in endovascular treatment of coronary heart disease: pathophysiology and therapeutic strategies (Review). Vestnik RGMU [Bulletin of the RSMU]. 2013; 4: 5–9.

7. Berezovskaya G.A., Karpenko M.A., Petrishchev N.N. Fibronectin – a risk factor or protection after intracoronary stenting? Regionarnoe krovoobraschenie i mikritsirkulyatsiya [Regional blood circulation and microcirculation]. 2013; 12 (4): 12–9. DOI: https://doi.org/10.24884/1682-6655-2013-12-4-12-19 (in Russian)

8. Veselovskaya N.G. Predicting the risk of restenosis of coronary arteries after their stenting in obese patients. Serdtse [Heart]. 2013; 12 (5): 305–10. (in Russian)

9. Alekyan B.G., Staferov A.V., Zakaryan N.V., Fozilov Kh.G. Types of complications due to percutaneous coronary interventions in patients with coronary heart disease. Grudnaya i serdechno-sosudistaya khirurgiya [Thoracic and cardiovascular surgery]. 2010; 6: 27–34. (in Russian)

10. Kovalenko I.B., Sudakov M.V., Zhernakova N.I., Shkodkin S.V., Dolzhikov A.A., Boyarincev M.I., Fentisov V.V. Endovascular treatment of patients with diseases of cardiovascular system: development stages, problems and the ways of their solving. Nauchnye vedomosti BelGU. Seriya: Medetsina. Farmatsiya [Scientific Bulletins of BelSU. Series: Medicine. Pharmacy]. 2011; 99 (4): 24–9/ (in Russian)

11. Maylyan D.E. In-stent restenosis: the current state of the problem. Nauchnye vedomosti BelGU. Seriya: Medetsina. Farmatsiya [Scientific Bulletins of BelSU. Series: Medicine. Pharmacy]. 2015; 207 (10), Issue 30: 5–12. (in Russian)

12. Osiev A.G., Mironenko S.P., Elkina D.S. Comparative characteristics of coated stents used in endovascular treatment of patients with coronary heart disease. Patologiya krovoobrascheniya i kardiokhirurgiya [Circulatory pathology and cardiac surgery]. 2013; 1: 91–5. (in Russian)

13. Prozorov S.A. Current approaches to the prevention, evaluation and treatment of complications during endovascular coronary artery interventions. Part I. Coronary artery ruptures. Neotlozhnaya meditsinskaya pomosch. Zhurnal imeni N.V. Sklifisofskogo [Sklifosovsky Journal Emergency Medical Care]. 2014; (2): 26–31. (in Russian)

14. Fozilov Kh.G. Complications of percutaneous coronary interventions, prevention and treatment: autoref. dis. ... candidate of medical Sciences. Moscow, 2011. P. 24. (in Russian)

15. Shuvalova Yu.A. Polymorphisms of the eNOS and GPx-1 genes are associated with risk of restenosis after coronary artery stenting with bare stents. Mezhdunarodnyy zhurnal interventsionnoy kardioangiologii [International journal of interventional cardioangiology]. 2011; 25: 47–53. (in Russian)

16. Yarbekov R.R., Chigogidze N.A., Sigaev I. Yu., Keren M.A. The early and mid-term results of percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease. Annaly khirurgii [Annals of surgery]. 2014; 5: 21–6. (in Russian)

17. Berezovskaya G.A., Ganyukov V.I., Karpenko M.A. Restenosis and in-stent stenosis: pathogenetic mechanisms and prognostic markers. Rossiyskiy kardiologicheskiy zhurnal [Russian journal of cardiology]. 2012; 6 (98): 91–5. (in Russian)

18. Shvalb P.G., Kalinin R.E., Ukhov Y.I Restenosis in reconstructive surgery of main arteries (cliniko-morphological research). Kardiologiya I serdechno-sosydistaya khirurgiya [Cardiology and cardiovascular surgery]. 2008; (4): 52–5. (in Russian)

19. Kaputin M. Yu., Ovcharenko D.V., Soroka V.V., Borovsky I.E., Dudanov I.P., Bregovskiy V.B. Transluminal balloon angioplasty in treatment of critical lower limb ischemia. Angiologiya i sosudistaya khirurgiya [Angiology and vascular surgery]. 2009; 15 (1): 142–7. (in Russian)

20. Stolyarov A.P., Fedorova M.G., Kharitonov E.A., Averkin N.S. Pathophysiological and morphological data on vascular changes after stent implantation. Izvestiya vuschikh uchebnukh zavedeniy. Privolzhskiy region. Meditsinskie nauki [University proceedings. Volga region. Medical sciences]. 2018; 2 (46): 131–43. (in Russian)

21. Palmerini T., Biondi-Zoccai G., Della Riva D., Mariani A., Sabaté M., Smits PC., Kaiser C., D’Ascenzo F., Frati G., Mancone M., Genereux P., Stone G.W. Clinical outcomes with bioabsorbable polymer versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014; 63 (4): 299–307. DOI: http://dx.doi.org/10.1016/j.jacc.2013.09.061

22. Cai A. Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement. Disease Markers. 2013; 35 (6): 857–62.

23. Grube E., Silber S., Hauptmann K.E., Mueller R., Buellesfeld L., Gerckens U., Russell M.E. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003; 107 (1): 38–42.

24. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., Dudek D., Fort S., Schiele F., Zmudka K., Guagliumi G., Russell M.E., TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003; 108 (7): 88–94.

25. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O’Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., Russell M.E., TAXUS-IV Investigators. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350 (3): 21–31.

26. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O’Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349 (14): 1315–23.

27. Babunashvili A.M. Efficiency of sirolimus-eluting stents in treatment of restenosis of coronary arteries after previous interventional procedures. Buylleten` NTSSSKH imeni A.N. Bakuleva RAMN [Bulletin of the A.N. Bakulev National Agricultural Academy of the Russian Academy of Medical Sciences]. 2006; 3: 45–6. (in Russian)

28. Parfyonova Ye.V., Tkachuk V.A. Perspectives of cardiovascular gene therapy. Voprosy meditsinskoi khimii [Questions of medical chemistry]. 2000; 46 (3): 293–310. (in Russian)

29. Prassolov V.S., Ivanov D.S. Retroviral vectors for gene therapy. Voprosy meditsinskoi khimii [Questions of medical chemistry]. 2000; 46 (3): 207–25. (in Russian)

30. Meredith I.T., Ormiston J., Whitbourn R., Kay I.P., Muller D., Bonan R., Popma J.J., Cutlip D.E., Fitzgerald P., Prpic R., Kuntz R.E. First-inhuman study of the Endeavor ABT-578-eluting phosphorylcholineencapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention. 2005; 1 (2): 157–64.

31. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Münzel T., Popma J.J., Fitzgerald P.J., Bonan R., Kuntz R.E., ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholineencapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006; 114 (8): 798–806. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.105.591206

32. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Münzel T., Popma J.J., Fitzgerald P.J., Bonan R., Kuntz R.E., ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol. 2007; 55 (1): 1–18. (In English, Italian)

33. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnàr F., Falotico R., RAVEL Study Group. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346 (23): 1773–80. DOI: https://doi.org/10.1056/NEJMoa012843

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)